Brokerages Set aTyr Pharma, Inc. (NASDAQ:ATYR) Price Target at $23.25

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have received an average recommendation of “Hold” from the eight brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $23.25.

ATYR has been the topic of a number of research reports. Wall Street Zen lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a research report on Wednesday, October 8th. Jones Trading lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. HC Wainwright lowered shares of aTyr Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, September 15th. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of aTyr Pharma in a research report on Monday, September 15th.

aTyr Pharma Stock Performance

ATYR stock opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. The stock has a market cap of $94.07 million, a P/E ratio of -1.20 and a beta of 0.79. The firm has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $3.87. aTyr Pharma has a 52 week low of $0.68 and a 52 week high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Research analysts anticipate that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other aTyr Pharma news, Director Paul Schimmel purchased 317,999 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were purchased at an average price of $0.94 per share, for a total transaction of $298,919.06. Following the completion of the purchase, the director directly owned 1,413,023 shares of the company’s stock, valued at approximately $1,328,241.62. This represents a 29.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On aTyr Pharma

Several institutional investors and hedge funds have recently made changes to their positions in ATYR. Cannon Global Investment Management LLC acquired a new stake in shares of aTyr Pharma in the 1st quarter valued at $143,000. Apollon Wealth Management LLC acquired a new stake in shares of aTyr Pharma in the 1st quarter valued at $71,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of aTyr Pharma in the 1st quarter valued at $38,000. Dauntless Investment Group LLC acquired a new stake in shares of aTyr Pharma in the 1st quarter valued at $515,000. Finally, GSA Capital Partners LLP boosted its stake in shares of aTyr Pharma by 21.1% in the 1st quarter. GSA Capital Partners LLP now owns 332,324 shares of the company’s stock valued at $1,004,000 after purchasing an additional 57,898 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.